S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
Indian tycoon Adani hit by more losses, calls for probe
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
Indian tycoon Adani hit by more losses, calls for probe
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
Indian tycoon Adani hit by more losses, calls for probe
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
A gold storm is coming… (Ad)
Bright Green Corporation Future May be Getting Brighter
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Closing prices for crude oil, gold and other commodities
Indian tycoon Adani hit by more losses, calls for probe
NASDAQ:ANIP

ANI Pharmaceuticals - ANIP Stock Forecast, Price & News

$44.67
-0.54 (-1.19%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$44.09
$45.50
50-Day Range
$37.31
$45.21
52-Week Range
$22.31
$45.50
Volume
70,522 shs
Average Volume
68,592 shs
Market Capitalization
$780.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.00

ANI Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
9.7% Upside
$49.00 Price Target
Short Interest
Healthy
1.86% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.98
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
227.27%
From $0.66 to $2.16 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

678th out of 1,029 stocks

Pharmaceutical Preparations Industry

341st out of 501 stocks

ANIP stock logo

About ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANIP Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
ANI Pharma: FDA Approves ANDA For Fluoxetine Oral Solution
This Biopharma 'Fits the Bill' as a Growth Play
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
ANI Pharmaceuticals, Inc. Q3 Earnings Summary
ANI Pharmaceuticals Appoints Krista Davis as...
Full-Year 2022 Guidance:
See More Headlines
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANIP Company Calendar

Last Earnings
11/09/2022
Today
2/03/2023
Next Earnings (Estimated)
3/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
Employees
601
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$49.00
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+9.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-42,600,000.00
Pretax Margin
-31.01%

Debt

Sales & Book Value

Annual Sales
$216.14 million
Cash Flow
$4.75 per share
Book Value
$19.73 per share

Miscellaneous

Free Float
12,715,000
Market Cap
$780.38 million
Optionable
Optionable
Beta
1.05

Key Executives

  • Nikhil LalwaniNikhil Lalwani
    President, Chief Executive Officer & Director
  • James G. Marken
    Senior VP-Operations & Product Development
  • Stephen P. CareyStephen P. Carey
    Chief Financial Officer & Senior VP-Finance
  • Muthusamy ShanmugamMuthusamy Shanmugam
    Director & Head-Research & Development
  • Mary Pao
    Chief Medical Officer













ANIP Stock - Frequently Asked Questions

Should I buy or sell ANI Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings
or view top-rated stocks.

What is ANI Pharmaceuticals' stock price forecast for 2023?

3 equities research analysts have issued 12 month target prices for ANI Pharmaceuticals' shares. Their ANIP share price forecasts range from $48.00 to $50.00. On average, they anticipate the company's stock price to reach $49.00 in the next twelve months. This suggests a possible upside of 9.8% from the stock's current price.
View analysts price targets for ANIP
or view top-rated stocks among Wall Street analysts.

How have ANIP shares performed in 2023?

ANI Pharmaceuticals' stock was trading at $40.23 at the beginning of 2023. Since then, ANIP shares have increased by 10.9% and is now trading at $44.63.
View the best growth stocks for 2023 here
.

When is ANI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our ANIP earnings forecast
.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued its earnings results on Wednesday, November, 9th. The specialty pharmaceutical company reported $0.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.40 by $0.06. The specialty pharmaceutical company had revenue of $83.82 million for the quarter, compared to analysts' expectations of $78.71 million. ANI Pharmaceuticals had a positive trailing twelve-month return on equity of 2.65% and a negative net margin of 23.95%.

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals issued an update on its FY 2022 earnings guidance on Friday, December, 9th. The company provided EPS guidance of $1.34-$1.62 for the period, compared to the consensus EPS estimate of $1.37. The company issued revenue guidance of $295.00 million-$315.00 million, compared to the consensus revenue estimate of $302.88 million.

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.71%), Comerica Bank (0.27%), DekaBank Deutsche Girozentrale (0.06%), BTC Capital Management Inc. (0.05%), Yousif Capital Management LLC (0.04%) and Louisiana State Employees Retirement System (0.03%). Insiders that own company stock include James G Marken, Jeanne Thoma, Muthusamy Shanmugam, Nikhil Lalwani, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends
.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $44.63.

How much money does ANI Pharmaceuticals make?

ANI Pharmaceuticals (NASDAQ:ANIP) has a market capitalization of $779.69 million and generates $216.14 million in revenue each year. The specialty pharmaceutical company earns $-42,600,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis.

How many employees does ANI Pharmaceuticals have?

The company employs 601 workers across the globe.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The official website for the company is www.anipharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at ir@anipharmaceuticals.com, or via fax at 218-634-3540.

This page (NASDAQ:ANIP) was last updated on 2/4/2023 by MarketBeat.com Staff